An EU e-liquid manufacturer.
Various analytes were detected in emissions from an e-liquid product using high performance liquid chromatography-mass spectrometry (HPLC-MS) and reported to bibra. Some of these chemicals (all carbonyls) were considered critical to the consumer health risk assessment of inhaled e-liquid products (including e‑cigarettes).
Bibra was asked to conduct a preliminary assessment of the health risks posed by the detected carbonyls in marketed e-liquids.
Searches for key toxicity data were carried out using bibra’s in-house database, TRACE. The key data were summarised by bibra toxicologists, with a focus on available health criteria values (HCVs) derived by Expert Groups (particularly inhalation HCVs, where available). Key local and systemic (cancer and non-cancer) points of departure (PoDs) for risk assessment were identified and described. These were compared to estimated consumer exposures, as calculated by bibra. A consideration of the possible additive effect of these carbonyls was included in the risk assessment report, as they are expected to have a similar mode-of-action (MoA).
Bibra supplied the client with a consumer health risk assessment of the emission compounds identified as critical, which included brief hazard monographs on each of the key carbonyls.
More recent work
Info about us
Meet our team